This HTML5 document contains 112 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33487992
rdf:type
wikibase:Item
schema:description
১৯৯৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 1994년 논문 artigo científico (publicado na 1994) artículo científico publicado en 1994 мақолаи илмӣ vitenskapelig artikkel 1994年论文 научная статья სამეცნიერო სტატია mokslinis straipsnis 1994年論文 articol științific teaduslik artikkel سائنسی مضمون wetenschappelijk artikel 1994年论文 1994年の論文 scientific article vitskapeleg artikkel מאמר מדעי artigo científico บทความทางวิทยาศาสตร์ научни чланак vetenskaplig artikel vedecký článok 1994年論文 tieteellinen artikkeli 1994年论文 artikull shkencor artykuł naukowy artículu científicu espublizáu en 1994 artigo científico (publicado na 1994) научни чланак tudományos cikk επιστημονικό άρθρο 1994年论文 1994 թվականի հոտեմբերին հրատարակված գիտական հոդված 1994年論文 مقالة علمية 1994 nî lūn-bûn 1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած articolo scientifico article científic naučni članak scienca artikolo مقالهٔ علمی 1994年论文 научна статия 1994年論文 мақолаи илмӣ bài báo khoa học bilimsel makale vědecký článek article scientific 1994年論文 wissenschaftlicher Artikel article scientifique (publié 1994) 1994年论文 artikulong pang-agham videnskabelig artikel (udgivet 1994) наукова стаття, опублікована в жовтні 1994
p:P577
wds:Q33487992-9CDDE67B-FDC8-442F-A256-A193725D1A69
wdt:P577
1994-10-01T00:00:00Z
p:P407
wds:Q33487992-9ED0FE23-586C-4366-BAF0-4698102293CA
wdt:P407
wd:Q1860
p:P2093
wds:Q33487992-C267B1F2-F3D9-4014-96ED-EE1F8C96A6F8 wds:Q33487992-C6DF9E55-9585-4273-94FF-EC13296DB05C wds:Q33487992-A31E5A43-1DA4-41B2-B658-1557EEDECCD4 wds:Q33487992-3763EA03-A853-4D81-84C2-FB8137842580 wds:Q33487992-27230513-CFC9-4C53-9D49-8F045B7AD79D wds:Q33487992-287A51EA-DA22-433D-AFC7-98679AE73004 wds:Q33487992-64B41040-FC4C-4BE7-90C7-3AB27B60CE62
wdt:P2093
Maloney DG Czerwinski DK Liles TM Grillo-Lopez A Waldichuk C Rosenberg J Levy R
rdfs:label
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
skos:prefLabel
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
schema:name
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
p:P1476
wds:Q33487992-104CCF19-C160-4DC9-879C-BD764F977C79
wdt:P1476
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
p:P304
wds:Q33487992-34601032-AF2F-4749-A908-65DE4F265D6E
wdt:P304
2457-2466
p:P31
wds:Q33487992-3CF24480-11EA-4726-894C-5D8C3008A3AA
wdt:P31
wd:Q13442814
p:P921
wds:Q33487992-8381CB76-F6EB-47A1-95B7-86D1E05097BC wds:Q33487992-3AFF3E73-7377-4861-8465-4251D4295BC0 wds:Q33487992-43A6BA95-A63E-4A4F-8811-C2FB16639595 wds:Q33487992-318ADB2B-0677-4E49-81E8-76ECC60152C8
wdt:P921
wd:Q79460 wd:Q422248 wd:Q412323 wd:Q5452194
p:P698
wds:Q33487992-E2F23B3F-674B-48B2-A502-0FA0C2CBCFA9
wdtn:P698
n11:7522629
wdt:P698
7522629
p:P1433
wds:Q33487992-92209997-C3C2-49DB-85E2-EBA63F48DF2B
wdt:P1433
wd:Q885070
p:P433
wds:Q33487992-3224A335-4A8D-402F-A123-B1D1C512169B
p:P478
wds:Q33487992-42C50D4B-F059-4205-AB21-C6A55F00E552
wdt:P433
8
wdt:P478
84